Ikena Oncology Inc (IKNA)

$1.38 -0.01 (-0.72%)
Market Cap 66.60M
Revenue (ttm) 0.00
Net Income (ttm) -49.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 40,200
Avg Vol 89,756
Day's Range N/A - N/A
Shares Out 48.26M
Stochastic %K 64%
Beta 0.50
Analysts Strong Sell
Price Target $4.00

Company Profile

Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 857 273 8343
Address:
645 Summer Street, Suite 101, Boston, United States
Sarahsanjose2
Sarahsanjose2 Jul. 11 at 1:20 PM
$IKNA July 15 vote
0 · Reply
Sarahsanjose2
Sarahsanjose2 Jul. 8 at 2:53 PM
$IKNA let’s go to 50$
0 · Reply
Livinglifewithlivingston
Livinglifewithlivingston Jul. 7 at 7:02 PM
$IKNA
1 · Reply
Sarahsanjose2
Sarahsanjose2 Jun. 27 at 3:58 PM
$IKNA anybody home????? Ghost town here
0 · Reply
Sarahsanjose2
Sarahsanjose2 Jun. 24 at 8:20 PM
$IKNA why it has to close at $1:30 and $1:40?
0 · Reply
Sarahsanjose2
Sarahsanjose2 Jun. 17 at 3:34 PM
$IKNA when is the merger date?
0 · Reply
BRT1991
BRT1991 Jun. 16 at 4:27 PM
$IKNA
1 · Reply
Sarahsanjose2
Sarahsanjose2 Jun. 12 at 7:39 PM
$IKNA
0 · Reply
Sarahsanjose2
Sarahsanjose2 Jun. 12 at 5:36 PM
$IKNA silently going up
0 · Reply
RiZzBoTt
RiZzBoTt Jun. 10 at 2:27 PM
$IKNA Still holding a good chunk . Merger news any day now......I hope
0 · Reply
Latest News on IKNA
Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals

Jul 11, 2025, 8:00 AM EDT - 2 days ago

Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

Dec 23, 2024, 8:37 AM EST - 7 months ago

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

Ikena Oncology Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 8:30 AM EST - 8 months ago

Ikena Oncology Reports Third Quarter 2024 Financial Results

Ikena Oncology Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 4:15 PM EDT - 1 year ago

Ikena Oncology Reports Second Quarter 2024 Financial Results

UPDATE – Ikena Oncology Announces Strategic Update

May 28, 2024, 4:42 PM EDT - 1 year ago

UPDATE – Ikena Oncology Announces Strategic Update

Ikena Oncology Announces Strategic Update

May 28, 2024, 4:15 PM EDT - 1 year ago

Ikena Oncology Announces Strategic Update

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

May 13, 2024, 4:45 PM EDT - 1 year ago

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

Feb 27, 2024, 8:00 AM EST - 1 year ago

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Feb 21, 2024, 4:15 PM EST - 1 year ago

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

Jan 18, 2024, 4:05 PM EST - 1 year ago

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 7:00 AM EST - 1 year ago

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Ikena Oncology to Present at Multiple November 2023 Investor Conferences

Nov 7, 2023, 8:00 AM EST - 1 year ago

Ikena Oncology to Present at Multiple November 2023 Investor Conferences

Ikena Oncology to Participate in September 2023 Investor Conferences

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Ikena Oncology to Participate in September 2023 Investor Conferences

Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Ikena Oncology to Participate in Upcoming Investor Conferences

May 24, 2023, 8:00 AM EDT - 2 years ago

Ikena Oncology to Participate in Upcoming Investor Conferences

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

May 15, 2023, 7:50 AM EDT - 2 years ago

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

Ikena Oncology Announces $40 Million Underwritten Offering

May 15, 2023, 7:45 AM EDT - 2 years ago

Ikena Oncology Announces $40 Million Underwritten Offering

Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Apr 20, 2023, 8:00 AM EDT - 2 years ago

Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

Apr 17, 2023, 9:00 AM EDT - 2 years ago

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 14, 2023, 7:00 AM EDT - 2 years ago

Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting

Mar 7, 2023, 8:00 AM EST - 2 years ago

Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting

Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma

Mar 6, 2023, 8:00 AM EST - 2 years ago

Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma

Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference

Feb 28, 2023, 8:00 AM EST - 2 years ago

Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference

Ikena Oncology Appoints Owen Hughes as Board Chair

Dec 19, 2022, 4:30 PM EST - 2 years ago

Ikena Oncology Appoints Owen Hughes as Board Chair

Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update

Nov 28, 2022, 8:00 AM EST - 2 years ago

Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update

Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference

Nov 22, 2022, 7:30 AM EST - 2 years ago

Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference

Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma

Nov 10, 2022, 9:00 AM EST - 2 years ago

Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma

UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Nov 7, 2022, 8:48 AM EST - 2 years ago

UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Nov 7, 2022, 8:05 AM EST - 2 years ago

Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance

Oct 26, 2022, 7:30 AM EDT - 2 years ago

Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance

Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway

Oct 18, 2022, 7:30 AM EDT - 2 years ago

Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway

Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Oct 5, 2022, 8:05 AM EDT - 3 years ago

Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Ikena Oncology to Participate in September 2022 Investor Conferences

Sep 6, 2022, 7:30 AM EDT - 3 years ago

Ikena Oncology to Participate in September 2022 Investor Conferences

Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Aug 11, 2022, 7:30 AM EDT - 3 years ago

Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022

Jul 6, 2022, 7:00 AM EDT - 3 years ago

Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022

Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma

Jun 22, 2022, 7:00 AM EDT - 3 years ago

Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma

Ikena Oncology to Participate in Spring 2022 Investor Conferences

May 18, 2022, 7:00 AM EDT - 3 years ago

Ikena Oncology to Participate in Spring 2022 Investor Conferences

Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update

May 12, 2022, 7:00 AM EDT - 3 years ago

Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer

May 3, 2022, 8:00 AM EDT - 3 years ago

Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer

Ikena Oncology and Vall d'Hebron Institute of Oncology Announce Research & Development Collaboration

May 2, 2022, 7:00 AM EDT - 3 years ago

Ikena Oncology and Vall d'Hebron Institute of Oncology Announce Research & Development Collaboration

Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Apr 28, 2022, 7:00 AM EDT - 3 years ago

Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development

Apr 13, 2022, 7:00 AM EDT - 3 years ago

Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development

Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Mar 17, 2022, 7:00 AM EDT - 3 years ago

Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Mar 7, 2022, 4:30 PM EST - 3 years ago

Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Ikena Oncology to Participate in Cowen 42nd Annual Health Care Conference

Mar 1, 2022, 7:00 AM EST - 3 years ago

Ikena Oncology to Participate in Cowen 42nd Annual Health Care Conference

Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors

Jan 26, 2022, 7:00 AM EST - 3 years ago

Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors

Sarahsanjose2
Sarahsanjose2 Jul. 11 at 1:20 PM
$IKNA July 15 vote
0 · Reply
Sarahsanjose2
Sarahsanjose2 Jul. 8 at 2:53 PM
$IKNA let’s go to 50$
0 · Reply
Livinglifewithlivingston
Livinglifewithlivingston Jul. 7 at 7:02 PM
$IKNA
1 · Reply
Sarahsanjose2
Sarahsanjose2 Jun. 27 at 3:58 PM
$IKNA anybody home????? Ghost town here
0 · Reply
Sarahsanjose2
Sarahsanjose2 Jun. 24 at 8:20 PM
$IKNA why it has to close at $1:30 and $1:40?
0 · Reply
Sarahsanjose2
Sarahsanjose2 Jun. 17 at 3:34 PM
$IKNA when is the merger date?
0 · Reply
BRT1991
BRT1991 Jun. 16 at 4:27 PM
$IKNA
1 · Reply
Sarahsanjose2
Sarahsanjose2 Jun. 12 at 7:39 PM
$IKNA
0 · Reply
Sarahsanjose2
Sarahsanjose2 Jun. 12 at 5:36 PM
$IKNA silently going up
0 · Reply
RiZzBoTt
RiZzBoTt Jun. 10 at 2:27 PM
$IKNA Still holding a good chunk . Merger news any day now......I hope
0 · Reply
Sarahsanjose2
Sarahsanjose2 Jun. 9 at 3:48 PM
$IKNA silent gun$10
0 · Reply
WallStArb
WallStArb Jun. 9 at 9:53 AM
$IKNA 1.53 not too shabby
0 · Reply
PenkeTrading
PenkeTrading Jun. 7 at 10:29 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Ikena Oncology Inc. Is that bullish or bearish? $IKNA #RsiOverbought #NASDAQ
1 · Reply
Sarahsanjose2
Sarahsanjose2 Jun. 6 at 12:44 PM
$IKNA it’s coming up, it’s going up
0 · Reply
WallStArb
WallStArb Jun. 3 at 3:29 PM
$IKNA sold some - will buy them back on a retrace - not a ton but premature 1.38 - 1.42 and during the day 1.38 area - I am feeling like they will just slowly ramp and retrace until the deal closes - upward bias follow volume
2 · Reply
WallStArb
WallStArb Jun. 3 at 2:13 PM
$IKNA thing of beauty - buyers are likely PIPE participants like DeepTrack and will just push it up to fair value area
0 · Reply
WallStArb
WallStArb Jun. 3 at 11:37 AM
$PMVP I will likely take some $$$ out of other names I am in $IKNA and add to PMVP Thursday is a conference which I don’t expect much but I do expect this to catch a bid into the phase2 data in 6 - 10 weeks
1 · Reply
WallStArb
WallStArb Jun. 3 at 11:34 AM
$IKNA $1.42 - validation based on the PIPE buses puts PMVP price in the $2 area about $120M - it’s my largest position currently and just a waiting game like $TECX was when it was $AVRO
0 · Reply
WallStArb
WallStArb Jun. 3 at 9:06 AM
$IKNA 1.35 nice 30% upside move in last couple weeks - it should start to close the gap to the PIPE implied valuation at about $120M - figure it will trade at a discount but fully expect $1.75 +/- into the reverse merger
0 · Reply
WallStArb
WallStArb Jun. 2 at 6:53 PM
$IKNA 1.30 not too shabby
0 · Reply
JamesPond007
JamesPond007 Jun. 2 at 6:02 PM
$IKNA
0 · Reply
SmartContent
SmartContent Jun. 2 at 8:41 AM
$IKNA Is this merger with Inmagene a real turnaround moment, and does the post-merger entity have enough capital and direction to justify betting on a new identity? > Yes. With $175M cash and a lead asset in a hot space (OX40 immunology), this is a well-capitalized clean slate with upside.
0 · Reply